Kidney Transplant Patient with a Facial Redness / 대한이식학회지
The Journal of the Korean Society for Transplantation
;
: 238-241, 2015.
Artículo
en Coreano
| WPRIM
| ID: wpr-114108
ABSTRACT
Posttransplant erythrocytosis (PTE) is a common complication of renal transplantation, which can occur in approximately 10% to 15% of renal transplant patients and usually affects males with relatively good renal function. It is also associated with an increased incidence of thromboembolic events. Clinical manifestations of PTE include malaise, headache, plethora, lethargy, and dizziness. It is correlated with use of cyclosporin, gender, posttransplant renal function, and type of antihypertensive medication. The angiotensin receptor blocker (ARB) or angiotensin-converting enzyme inhibitor is preferred as an initial treatment for PTE because these agents are effective and reasonably safe in the majority of patients with PTE, and can also provide a necessary antihypertensive effect for kidney transplant patients. We report here on a 35-year-old male who had erythrocytosis after renal transplantation. After renal transplantation, his level of hemoglobin was 21 g/dL. We treated this patient with ARB and his symptoms and signs have been completely relieved.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Policitemia
/
Angiotensinas
/
Incidencia
/
Trasplante de Riñón
/
Ciclosporina
/
Mareo
/
Letargia
/
Antagonistas de Receptores de Angiotensina
/
Cefalea
/
Riñón
Tipo de estudio:
Estudio de incidencia
/
Estudio pronóstico
Límite:
Adulto
/
Humanos
/
Masculino
Idioma:
Coreano
Revista:
The Journal of the Korean Society for Transplantation
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS